Lytix Biopharma A/S

Business Description

Lytix Biopharma ASA is a Norwegian biotech company founded in 2003 and headquartered in Oslo, focused on developing new treatments that use the body's immune system to fight cancer. Its most advanced therapy, ruxotemitide, is injected directly into tumors and is currently being tested in late-stage clinical trials for melanoma, basal cell carcinoma, and soft tissue sarcoma, as well as in an earlier-stage trial alongside another cancer drug. The company is also working on a second treatment called LTX-401, aimed at hard-to-reach tumors such as liver cancer, which is still in early research. Lytix has partnered with Verrica Pharmaceuticals to bring ruxotemitide to market for a range of skin-related cancers in the United States.